Results 261 to 270 of about 3,746,725 (298)
Some of the next articles are maybe not open access.
Direct-acting antivirals: the endgame for hepatitis C?
Current Opinion in Virology, 2017Directly-acting antivirals (DAA) have finally allowed all patients to be potentially cured from chronic hepatitis C (HCV) infection. All-oral, Interferon (IFN)-free regimens are based upon the combination of molecules targeting different sites of the HCV replication process.
Roberta, D'Ambrosio +3 more
openaire +2 more sources
IL28B in the Era of Direct-acting Antivirals for Hepatitis C
Journal of Clinical Gastroenterology, 2013The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response ...
openaire +2 more sources
[Direct-acting antiviral-resistant variant].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, IFN-free NS5A inhibitor daclatasvir and protease inhibitor asunaprevir combination treatment was approved for genotype 1b HCV-infected patients who were ineligible or who failed to respond to previous therapies. NS5A inhibitor-resistant variants occasionally exist in HCV-infected patients who have never been exposed to direct-acting ...
Michio, Imamura, Kazuaki, Chayama
openaire +1 more source
Direct-acting antivirals for paediatric HCV: we got there
Nature Reviews Gastroenterology & Hepatology, 2017In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.
openaire +2 more sources
Direct-acting antiviral treatment for HCV
The Lancet Infectious Diseases, 2016Stelliana, Goutzamanis +4 more
openaire +2 more sources
Direct acting antiviral therapy after liver transplantation
Current Opinion in Gastroenterology, 2016Historically, postliver transplant patients with chronic hepatitis C have had worse outcomes than nonhepatitis C-related causes because of accelerated fibrosis posttransplantation and the lack of effective well tolerated therapies for hepatitis C, and posttransplant hepatitis C patients have been considered a special population.
openaire +2 more sources
Direct-Acting Antiviral Agents
Clinics in Liver Disease, 2015Tatyana Kushner, Vandana Khungar
openaire +1 more source
Direct-acting antiviral agents for the treatment of HCV
Antiviral Therapy, 2012Alexander J, Thompson +1 more
openaire +2 more sources
Direct-acting antiviral treatment for hepatitis C
The Lancet, 2019Jacinta A, Holmes +2 more
openaire +2 more sources
Direct‐acting antivirals and recurrence of hepatocellular carcinoma
Liver Transplantation, 2017Jorge A, Marrero, Amit G, Singal
openaire +2 more sources